Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S.-Japan supplement groups collaborate

This article was originally published in The Tan Sheet

Executive Summary

Representatives from the National Nutritional Foods Association of Japan and two U.S. supplement trade groups met in Tokyo June 6 to establish a working group to facilitate sharing regulatory and legislative information between the countries. The collaboration between NNFA-J, the Council for Responsible Nutrition and the Natural Products Association aims to increase Japanese consumers' access to supplements and foster trade between the U.S. and Japan, the groups say. NNFA-J plans to send a delegation to Washington to meet with CRN and NPA later this year. The groups plan to share information about regulations and legislation affecting issues including health claims, food safety and ingredients for food and supplement products...

You may also be interested in...



Small And Emerging Supplement Markets Offer Big Growth Opportunities

Dietary supplement manufacturers eager to expand their international business should consider the potential of the small but rapidly growing markets in Eastern and Western Europe and emerging Asian markets (see chart: "1Top Global Markets in 2006")

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel